15例COVID-19患者治疗后痰、粪便标本新型冠状病毒核酸检测结果比较

 

目的 探讨粪便样本作为疑似或确诊新型冠状病毒肺炎（COVID-19）患者筛查的可行性。方法 利用Real Time RT-PCR技术，对15 例COVID-19患者治疗后痰、粪便标本中新型冠状病毒的ORF1ab、N基因以及人体细胞管家基因核糖核酸酶P（ribonuclease P，RNase P）进行检测，比较痰、粪便标本检测阳性情况。结果 15例患者痰、粪便标本，人体细胞管家基因 RNase P均呈现典型的明显的扩增信号曲线。新型冠状病毒核酸检测，2例患者痰、粪便标本同时为阳性，4例患者痰、粪便标本分别为阳性；6例患者痰阳性标本中有2例同时扩增出ORF 1ab基因与N基因，6例患者粪便阳性标本中有4例同时扩增出ORF 1ab基因与N基因。结论 以呼吸道标本新型冠状病毒核酸检测阴性作为排除COVID-19及治愈标准在实施过程中需谨慎，可以尝试将粪便标本新型冠状病毒核酸检测阴性也纳入其中。

Comparison of 2019-nCoV test results of sputum and fecal specimens of 15 patients with COVID-19 after treatment

Objective To evaluate the feasibility of fecal specimens for screening coronavirus disease 2019 (COVID- 19) suspected or confirmed patients. Methods Novel coronavirus (2019-nCoV, SARS-CoV-2) ORF1ab, N gene and human cell housekeeping gene ribonuclease P (RNase P) in sputum and faecal specimens of 15 patients with COVID-19 after treatment were detected by real time RT-PCR, positive rates of sputum and faecal specimens were compared. Results Among sputum and faecal specimens of 15 patients, human cell housekeeper gene RNase P all showed typical and obvious amplification signal curve. Two patients were both positive for 2019-nCoV nucleic acid test of sputum and faecal specimens, while 4 patients were only sputum or fecal specimens positive respectively; among sputum positive specimens of 6 patients, only 2 were amplified ORF 1ab gene and N gene simultaneously, among fecal positive specimens of 6 patients, only 4 were all amplified ORF 1ab gene and N gene simultaneously. Conclusion Negative detection result of 2019-nCoV nucleic acid test of respiratory tract specimens as criterion for excluding and curing COVID-19 should be prudent, negative detection result of 2019-nCoV nucleic acid test for fecal specimens can be considered.